NEW CHINA LIFE INSURANCE COMPANY LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.6 CNY | +2.10% |
|
+3.49% | +4.72% |
| May. 08 | Nomura Adjusts New China Life’s Price Target to 30.01 Yuan From 33.07 Yuan, Keeps at Neutral | MT |
| May. 08 | Nomura Adjusts New China Life’s Price Target to HK$20.29 From HK$23.70, Keeps at Buy | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 60% by 2026.
- Its low valuation, with P/E ratio at 8.68 and 7.24 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.77 for the current period. Therefore, the company is undervalued.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.72% | 11.63B | C | ||
| +14.17% | 79.9B | B- | ||
| +10.42% | 51.72B | B+ | ||
| +4.45% | 48.91B | B | ||
| +21.07% | 46.79B | B+ | ||
| +15.01% | 42.67B | B+ | ||
| +27.87% | 40.79B | B | ||
| -1.01% | 29.55B | B- | ||
| +1.28% | 29.14B | B | ||
| -10.42% | 27.5B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 601336 Stock
- Ratings New China Life Insurance Company Ltd.
